Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
PHVS submitted a Form 144 notice disclosing proposed sales of restricted common stock by an affiliate. The filing lists two lots of restricted shares: 4,667 shares dated 04/11/2025 and 5,000 shares dated 03/12/2026.
The broker identified is Morgan Stanley Smith Barney LLC and the filing shows an amount of $292,853.06 alongside broker and exchange details. The filing is a routine affiliate resale notice under securities rules.
Pharvaris N.V.’s Chief Executive Officer, Berndt Modig, sold 2,292 shares of common stock in an open-market transaction. The sale on May 18, 2026 was executed at a weighted average price of $29.222 per share under a Rule 10b5-1 trading plan.
Following this transaction, Modig directly holds 137,500 shares of Pharvaris common stock. The footnote explains that the sold shares include stock previously acquired upon vesting of restricted stock units, and that individual sale prices ranged from $29.47 to $30.40.
PHVS submitted a Form 144/A notice listing proposed sales of Common Stock through Morgan Stanley Smith Barney LLC as broker-dealer. The filing lists 4,667 shares described as Restricted Stock dated 04/11/2025 and 5,333 shares from a Stock Option Exercise dated 05/15/2026 (cash).
Pharvaris N.V. director Robert Glassman reported an exercise-and-sell transaction in company stock. On May 15, 2026, he exercised stock options for 5,333 shares of common stock at a price of $22.31 per share, then sold a total of 10,000 shares in open-market transactions at weighted average prices around $29.82 per share. The sales were executed in multiple trades within price ranges disclosed in the footnotes, and his directly held stake after the transactions was 10,500 common shares. The option exercised was fully vested as of April 11, 2025.
Pharvaris N.V. Chief Technical Ops Officer Stefan Andreas Abele reported an open-market sale of common stock. He sold 8,748 shares at an average price of $29.8199 per share. After the transaction, he directly holds 35,194 shares.
The reported holdings include shares of common stock that were previously acquired upon vesting of restricted stock units on various dates, according to the accompanying footnote.
Pharvaris N.V. Chief Commercial Officer Wim Souverijns sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $29.9163 per share. The sale was executed on May 15, 2026 under a pre-arranged Rule 10b5-1 trading plan, and Souverijns held 45,111 shares after the transaction.
Pharvaris N.V. Schedule 13G/A amendment reports that Viking Global-related reporting persons beneficially own 3,653,310 ordinary shares, representing 5.6% of the class. Effective March 31, 2026, David C. Ott retired and was removed as a reporting person.
The filing cites 65,407,822 ordinary shares outstanding as of March 17, 2026 per the issuer's Form 20-F and attributes shared voting and dispositive power over the 3,653,310 shares to Viking Global entities and two executive committee members.